Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that its CEO, Douglas Love, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 p.m. ET. The presentation will focus on their innovative complement medicines targeting autoimmune and neurodegenerative disorders. A live webcast will be available on their website, with a replay accessible for 30 days post-event.
Annexon's pipeline includes product candidates like ANX005, ANX007, and ANX009, designed to disrupt the C1q pathway.
- None.
- None.
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
FAQ
What will Annexon present at the J.P. Morgan Healthcare Conference 2022?
When is Douglas Love's presentation at the J.P. Morgan Healthcare Conference?
How can I access the presentation from Annexon at the conference?
What products is Annexon developing related to complement medicines?
What is the focus of Annexon's clinical-stage pipeline?
